ASH 2022 | Synergistic combination of RAP-GRL & TMPRSS6-ASO in β-thalassemia
Stefano Rivella, PhD, Children’s Hospital of Philadelphia, Philadelphia, PA, comments on the potential of combining the TGF-β ligand trap RAP-GRL with an iron restriction therapy called TMPRSS6-ASO, which targets the matriptase-2 (TMPRSS6) gene using antisense oligonucleotides (ASO). Dr Rivella explains that the combination of these two drugs with different mechanisms of action helps improve anemia and normalize iron metabolism. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
BVF Partners L.P: Consultancy; Cambridge Healthcare Res: Consultancy; Catenion: Consultancy; Celgene: Consultancy; Disc Medicine: Current holder of stock options in a privately-held company, Membership on an entity’s Board of Directors or advisory committees; First Manhattan Co: Consultancy; FORMA: Consultancy; Ghost Tree Capita: Consultancy; Incyte: Membership on an entity’s Board of Directors or advisory committees; Ionis Pharmaceuticals: Membership on an entity’s Board of Directors or advisory committees; Keros Therapeutics: Consultancy; MeiraGTx: Consultancy; Noble insight: Consultancy; Protagonist Therapeutics: Consultancy; Rallybio, LLC: Consultancy; Sanofi Aventis U.S: Consultancy; Slingshot Insight: Consultancy; Techspert.io: Consultancy; venBio Select LLC: Consultancy; Vifor: Membership on an entity’s Board of Directors or advisory committees.
